Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Next Previous
X
Search
Trial Profile

A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Sponsors Ardelyx

    • Most Recent Events

    • 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
    • 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
    • 09 Aug 2017 Results from this trial are expected in the fourth quarter of 2017, according to an Ardelyx media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top